Drug Type Monoclonal antibody |
Synonyms Gevokizumab (USAN/INN), AB-7, S-78989 + [5] |
Target |
Mechanism IL-1β inhibitors(Interleukin-1 beta inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (US) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09911 | Gevokizumab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Behcet's uveitis | Phase 3 | US | 01 Nov 2014 | |
Pyoderma Gangrenosum | Phase 3 | US | 01 Nov 2014 | |
Pyoderma Gangrenosum | Phase 3 | AU | 01 Nov 2014 | |
Pyoderma Gangrenosum | Phase 3 | CA | 01 Nov 2014 | |
Ocular inflammation | Phase 3 | US | 01 Mar 2014 | |
Uveitis, Intermediate | Phase 3 | US | 04 Feb 2013 | |
Uveitis, Intermediate | Phase 3 | AR | 04 Feb 2013 | |
Uveitis, Intermediate | Phase 3 | AM | 04 Feb 2013 | |
Uveitis, Intermediate | Phase 3 | AU | 04 Feb 2013 | |
Uveitis, Intermediate | Phase 3 | AT | 04 Feb 2013 |
Phase 3 | 83 | egknefezxt(iyycquoiwb) = Gevokizumab did not significantly affect the risk of occurrence of ocular exacerbations. However, data suggested that gevokizumab could preserve visual acuity, reduce the uveitis severity, decrease the emergence of macular edema, and have a corticosteroid sparing effect. Gevokizumab was well tolerated qqbunszlqm (qlukdvvgjk ) | Negative | 01 Jan 2018 | |||
Placebo | |||||||
Phase 1/2 | 8 | qptahijuqx(diabitsmil) = xxrbpdknaw kggessschs (fbgdlvezkh ) | Positive | 01 Dec 2016 |